Literature DB >> 2029508

Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma.

J J Zwaginga1, M J IJsseldijk, P G de Groot, J Vos, R L de Bos Kuil, J J Sixma.   

Abstract

Uremia is associated with bleeding diathesis. Platelet adhesion to the subendothelium is inhibited by a factor in uremic plasma that may play a role in the disturbed hemostasis of uremic patients. In the formation of the hemostatic plug, platelet adherence is followed by stimulus-induced platelet aggregation and reinforcement by thrombin-generated fibrin. To study these processes in uremic blood, a newly developed thrombosis model was used. Perfusates anticoagulated with low-molecular-weight heparin were circulated over a matrix of stimulated cultured endothelial cells. By stimulation of the endothelial cells, tissue factor was synthesized and deposited in the matrix. When this tissue factor rich-matrix was exposed to flowing blood, local thrombin was formed via activation of the extrinsic coagulation pathway. With this system, platelet adhesion, thrombin-dependent platelet activation, and fibrin formation can all be studied at the same surface. In addition to an adhesion defect, decreased aggregate formation was also found in uremic perfusates. Normal platelets in uremic plasma showed similar results, which indicates that a factor in uremic plasma caused this adhesion and aggregation defect. Platelet aggregation in the system was dependent on endogenously formed thrombin. Fibrinopeptide A generation, however, was normal in uremic perfusates; therefore, uremic plasma has a normal capacity to form thrombin. Resuspension of washed uremic platelets in control plasma did not reverse the aggregation defect in perfusions. In contrast, aggregometer studies with isolated uremic platelets could not detect an abnormal response to threshold concentrations of exogenous thrombin. Thus, uremic toxin(s) cause defective aggregate formation in flow, but not necessarily in the aggregometer. This apparent discrepancy may be due to the higher shear forces in the flow system, which may prevent aggregate formation that is allowed in the aggregometer. Another explanation, that uremic platelets are less responsive to locally formed thrombin than they are to exogenously added thrombin, seems less likely.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2029508     DOI: 10.1161/01.atv.11.3.733

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  9 in total

1.  Abnormal cytoskeletal assembly in platelets from uremic patients.

Authors:  G Escolar; M Díaz-Ricart; A Cases; R Castillo; A Ordinas; J G White
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

2.  Effects of Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose Injection on the levels of main platelet thrombin receptors in chronic haemodialysis patients.

Authors:  Yan Li; Lin Shen; Rui Chen; Jing Li; Fu-rong Lu; You Qin; Jan-guo Liu
Journal:  Chin J Integr Med       Date:  2011-08-09       Impact factor: 1.978

Review 3.  Platelets in liver and renal disease.

Authors:  Michele P Lambert
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 4.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

5.  Role of Platelets in Chronic Kidney Disease.

Authors:  Nishank Jain; Adam Corken; Amudha Kumar; Clayton Davis; Jerry Ware; John Arthur
Journal:  J Am Soc Nephrol       Date:  2021-06-17       Impact factor: 14.978

6.  A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease.

Authors:  Donald F Brophy; Rika J Martin; Todd Wb Gehr; Marcus E Carr
Journal:  Thromb J       Date:  2005-03-29

7.  Evaluation of hemostasis in patients with end-stage renal disease.

Authors:  Anja Gäckler; Hana Rohn; Ton Lisman; Tamas Benkö; Oliver Witzke; Andreas Kribben; Fuat H Saner
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240

8.  Retrospective analysis of nontraumatic subdural hematoma incidence and outcomes in Egyptian patients with end-stage renal disease on hemodialysis.

Authors:  Ahmed Fayed; Ayman Tarek; Mohamed I Refaat; Sameh Abouzeid; Sohail Abdul Salim; Lajos Zsom; Tibor Fülöp; Karim M Soliman; Mohamed A Elmallawany
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

9.  Whole blood platelet aggregation and release reaction testing in uremic patients.

Authors:  Jay Zeck; Jason Schallheim; Susie Q Lew; Louis DePalma
Journal:  Biomed Res Int       Date:  2013-06-26       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.